177477-97-3

Upstream product

• 174298-69-2 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 82617-30-9 (2,6-dimethyl-3-nitrophenyl)methyl acetate 
• 82617-29-6 2,6-dimethyl-3-nitrobenzene-1-methanol 
• 62346-87-6 2,6-dimethylbenzyl acetate 
• 62285-58-9 2,6-dimethylbenzyl alcohol 
• 177477-96-2 4-{(E)-2-[({[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-methyl-carbamoyl}-methyl)-carbamoyl]-vinyl}-N-methyl-benzamide 
• 174298-71-6 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-methyl-acetamide 
• 174298-70-5 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide 
• 174298-72-7 3-(N-Glycyl-N-methylamino)-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 174298-68-1 tert-Butyl-(2,6-dimethyl-3-nitro-benzyloxy)-diphenyl-silane 

Downstream Products

• 177477-98-4 1-chloromethyl-2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzene 
• 177478-40-9 3-[2,6-Dimethyl-3-[N-[4-(methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-amino-N-methylaniline 
• 177477-46-2 4-[2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-mercapto-1-methyl-1H-benzimidazole 

Relevant academic research and scientific papers

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

Quinoline derivatives as bradykinin agonists

PCT No. PCT/JP97/00233 Sec. 371 Date Aug. 3, 1998 Sec. 102(e) Date Aug. 3, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/28153 PCT Pub. Date Aug. 7, 1997This invention relates to a compound of formula (1) wherein R1 is halogen, etc., R2 is halogen, etc., R3 is amino substituted with substituent(s) selected from the group consisting of lower alkyl and acyl, etc., R4 is heterocyclic (lower)alkyl, R5 is lower alkyl, and A1 is lower alkylene, and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of hypertension or the like.

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]